Filter By Category
Archives
Share on -
AMIBEGRON
Generic Name: AMIBEGRON
ABSTRACT -
Amibegron (SR-58611A) is an investigational selective beta-3 adrenergic receptor agonist that was studied for depression, anxiety-related disorders, and functional gastrointestinal conditions. It was designed as an orally active agent capable of central nervous system penetration. Development for depression and generalized anxiety disorder was discontinued, and it is not a routine marketed medicine.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- No approved dosing regimen is available.
- Clinical-trial dosing was oral and protocol-specific.
- Do not use outside authorized research or specialist investigational settings.
SIDE EFFECTS–
Possible side effects and safety concerns include:
- Headache
- Nausea, abdominal discomfort, diarrhoea, or constipation
- Dizziness
- Insomnia or sleep disturbance
- Palpitations, tachycardia, or blood-pressure change
- Anxiety, restlessness, or mood changes
- Hypersensitivity reactions
ALLRGIC REACTIONS–
Hypersensitivity to Amibegron or related compounds/products may occur. Symptoms may include:
- Rash
- Urticaria
- Facial swelling
- Wheezing
- Anaphylaxis
Important: Patients who develop an allergic reaction to Amibegron should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS–
Amibegron may interact with certain medicines, vaccines, protocols, or clinical conditions. Caution is needed with:
- Other beta-adrenergic agonists or sympathomimetics may increase cardiovascular effects.
- Beta-blockers may reduce pharmacodynamic effects.
- Psychiatric medicines require review because of overlapping CNS effects.
- Medicines affecting heart rate, blood pressure, or anxiety symptoms require caution.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Assess cardiovascular status before investigational use.
- Monitor blood pressure, pulse, sleep, mood, anxiety, and gastrointestinal symptoms.
- Use caution in uncontrolled hypertension, arrhythmia, severe anxiety, or bipolar disorder.
- Pregnancy and lactation safety are not established.
WARNINGS –
- Amibegron development was discontinued and the drug is not approved for routine treatment.
- Do not use as a substitute for approved antidepressant, anxiolytic, or gastrointestinal therapy.
- Adrenergic agents may worsen cardiovascular or psychiatric symptoms in susceptible patients.
- Keep out of reach of children.
Share on -
. Developed by